SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

This trial is comparing SHR-A1811 — a new antibody-drug conjugate targeting HER2 — to standard chemotherapy chosen by the doctor for women with HER2-low hormone receptor-positive metastatic breast cancer that no longer benefits from hormone therapy. **You may be eligible if...** - You have breast cancer with low HER2 expression (IHC 2+/ISH-negative or IHC 1+) - Your cancer is hormone receptor-positive but has stopped responding to hormone therapy - You have had 0–1 prior lines of chemotherapy for metastatic disease - Your cancer has measurable, progressing disease on imaging - You are in adequate overall health **You may NOT be eligible if...** - You have HER2-negative (IHC 0) or HER2-high (overexpressing) breast cancer - You have had 2 or more prior lines of chemotherapy for metastatic breast cancer - You are still responding to hormone therapy - You have uncontrolled brain metastases Talk to your doctor to see if this trial is right for you.